Results 101 to 110 of about 3,283 (198)

One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema

, 2023
Ryan B Rush1– 3 1Panhandle Eye Group, Amarillo, TX, USA; 2Southwest Retina Specialists, Amarillo, TX, USA; 3Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USACorrespondence: Ryan B Rush, Southwest Retina Specialists ...
Rush RB
core  

Resolution of Angiographic Macular Leakage with Faricimab Versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE [PDF]

Purpose: To evaluate if dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor-A (VEGF-A) inhibition with faricimab resulted in greater macular leakage resolution versus aflibercept in patients with diabetic macular edema (DME).
Vujosevic, Stela, Shildkrot, Yevgeniy Eugene, Mar, Florie A, Udaondo, Patricia, Sivaprasad, Sobha, Wang, Tracey, Souverain, Audrey, Csaky, Karl, Goldberg, Roger A, Gibson, Kara, Amador, Manuel, Nudleman, Eric, Kolomeyer, Anton M, Murata, Toshinori, Sim, Dawn A, Khanani, Arshad M   +15 more
core   +1 more source

Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care

Ophthalmology and Therapy
Introduction Neovascular age-related macular degeneration (nAMD) is a chronic, vision-threatening condition requiring ongoing anti-vascular endothelial growth factor (anti-VEGF) injections.
Yaneth Gil-Rojas, Luke Nicholson, Sebastien Eymere, Oliver Cox, Marloes Bagijn   +4 more
doaj   +1 more source

Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients.

American journal of ophthalmology-glaucoma
PURPOSE To describe the patient characteristics and clinical course of severe intraocular inflammation (IOI) following intravitreal injection (IVT) of faricimab. DESIGN Retrospective case series. METHODS Case series at a single French academic center
I. Ben Ghezala, P. Gabrielle, Maxime Sibert, Laure-Anne Steinberg, A. Dautriche, Louis Arnould, C. Creuzot-Garcher   +6 more
semanticscholar   +1 more source

Recurrent uveitic macular edema managed with intravitreal faricimab injection

Journal of Ophthalmic Inflammation and Infection
Purpose To present a case of recurrent uveitic macular edema (UME) treated with intravitreal faricimab injection. Methods Single case report from a tertiary referral center. Observations A 63-year-old Caucasian female presenting with recurrent UME due to
Negin Yavari, Dalia El Feky, Frances A. Anover, Khiem Nguyen, Azadeh Mobasserian, Quan Dong Nguyen, Christopher Or   +6 more
doaj   +1 more source

Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis

BMJ Open Ophthalmology
Objective To evaluate the efficacy and safety of faricimab compared with other anti-vascular endothelial growth factor (anti-VEGF) agents in treating neovascular age-related macular degeneration (nAMD) patients.Methods and analysis A systematic review ...
Francisco Rodríguez, Daniel Samacá-Samacá, Claudia Hernández-Castillo, Laura Prieto-Pinto, Carolina Sardi, Hugo Ocampo, Joshua Kock, Fabián Hernández   +7 more
doaj   +1 more source

Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes

Graefe's Archive for Clinical and Experimental Ophthalmology
Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are not sustained over
H. Agostini, Francis Abreu, C. Baumal, Dolly S. Chang, Karl G. Csaky, A. Demetriades, L. Kodjikian, Jennifer I. Lim, Philippe Margaron, J. Monés, T. Peto, F. Ricci, Matthias Rüth, Rishi P. Singh, I. Stoilov, Balakumar Swaminathan, Jeffrey R. Willis, Peter D. Westenskow   +17 more
semanticscholar   +1 more source

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Ophthalmology and Therapy
This is a summary of the original article “Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US”.
Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh A. Patel   +5 more
doaj   +1 more source

Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis

Ophthalmology and Therapy
To evaluate the outcomes of intravitreal faricimab (IVF; Vabysmo®) in previously treated patients with wet age-related macular degeneration (wAMD), focusing on best available visual acuity (BAVA), central subfield thickness (CST), injection interval ...
Ali Khodor, J. Caranfa, Tavish Nanda, Raul E. Ruiz-Lozano, M. E. Quiroga-Garza, Stephanie Choi, Ali Chehab, Eugenia M. Ramos-Dávila, Jeffrey S. Heier, Chirag P. Shah, A. Witkin   +10 more
semanticscholar   +1 more source

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

, 2023
Ryan B Rush1– 3 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Ophthalmology, Southwest Retina Specialists, Amarillo, TX, USA; 3Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX ...
Rush RB
core